Zogenix has announced that it has reached an agreement with Valeant to begin selling Migranal dihydroergotamine mesylate nasal spray in the US beginning in late July 2013 and extending initially through the end of 2015. Valeant will pay Zogenix a quarterly service fee based on a percentage of sales exceeding a specified baseline.
Zogenix CEO Roger L. Hawley commented, “We are pleased to enter a co-promotion agreement with Valeant for Migranal Nasal Spray. We view Migranal as complementary to Sumavel DosePro and supportive of the migraine treatment guidelines, which encourage the use of a toolbox of treatment options to address the variety in migraine attacks. We believe that our sales force is well positioned to expand adoption of Migranal with neurologists and headache specialists that prescribe Sumavel DosePro, providing more patients with this treatment option. We believe this agreement fits well with our vision to be the leading specialty migraine company and help drive our commercial operations towards profitability.”
Sumavel DosePro is a needle-free sumatriptan injection for the treatment of migraine, and the company suggests that the dihydroergotamine nasal spray may benefit patients who do not respond to triptans.
Read the Zogenix press release.
